Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137330 | Leukemia Research | 2011 | 7 Pages |
Abstract
Leukemic cells from 230 children with newly diagnosed B-cell precursor ALL were tested for in vitro drug resistance to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. During follow-up, 24 relapses occurred in the 159 children with MRD <0.1% day 29. The risk of any relapse was correlated to vincristine and doxorubicin resistance, with a relative risk of 3.7 (95% CI 1.3-10.5; p = 0.016) for patients resistant to both drugs. There was a significant correlation also for the subgroup with extra-medullary relapses. Our findings indicate that analysis of drug resistance can add prognostic information to other known risk-factors including MRD.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gudmar Lönnerholm, Ingrid Thörn, Christer Sundström, Britt-Marie Frost, Trond Flaegstad, Mats Heyman, Olafur Gisli Jonsson, Arja Harila-Saari, Hans O. Madsen, Anna Porwit, Kjeld Schmiegelow, Stefan Söderhäll, Finn Wesenberg, Kim Vettenranta,